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OBJECTIVES The purpose of this study was to compare recombinant hirudin and heparin as adjuncts to
streptokinase thrombolysis in patients with acute myocardial infarction (AMI).
BACKGROUND Experimental studies and previous small clinical trials suggest that specific thrombin inhibition
improves early patency rates and clinical outcome in patients treated with streptokinase.
METHODS In a randomized double-blind, multicenter trial, 1,208 patients with AMI #6 h were treated
with aspirin and streptokinase and randomized to receive recombinant hirudin (lepirudin, IV
bolus of 0.2 mg/kg, followed by subcutaneous (SC) injections of 0.5 mg/kg b.i.d. for 5 to 7
days) or heparin (IV placebo bolus, followed by SC injections of 12,500 IU b.i.d. for 5 to 7
days). A total of 447 patients were included in the angiographic substudy in which the
primary end point, 90-min Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 of
the infarct-related artery, was evaluated, while the other two-thirds served as “safety group”
in which only clinical end points were evaluated. As an additional efficacy parameter the
ST-segment resolution at 90 and 180 min was measured in all patients.
RESULTS TIMI flow grade 3 was observed in 40.7% in the lepirudin and in 33.5% in the heparin group
(p 5 0.16), respectively. In the entire study population the proportion of patients with
complete ST resolution at 90 min (28% vs. 22%, p 5 0.05) and at 180 min (52% vs. 48%, p 5
0.18) after start of therapy tended to be higher in the lepirudin group. There was no
significant difference in the incidence of hemorrhagic stroke (0.2% vs. 0.3%) or total stroke
(1.2% vs. 1.5%), reinfarction rate (4.6% vs. 5.1%) and total mortality rate (6.8% vs. 6.4%) at
30 days, as well as the combined end point of death, nonfatal stroke, nonfatal reinfarction,
rescue-percutaneous transluminal coronary angioplasty and refractory angina (22.7 vs. 24.3%)
were not statistically different between the two groups.
CONCLUSIONS Lepirudin as adjunct to thrombolysis with streptokinase did not significantly improve
restoration of blood flow in the infarct vessel as assessed by angiography, but was associated
with an accelerated ST resolution. There was no increase in the risk of major bleedings with
lepirudin compared to heparin. (J Am Coll Cardiol 1999;34:966–73) © 1999 by the
American College of Cardiology
Thrombolytic therapy has been shown to preserve ventric-
ular function and improve survival in patients with acute
myocardial infarction (AMI) (1,2). Several angiographic
studies have demonstrated that an unimpaired flow
(Thrombolysis in Myocardial Infarction [TIMI] grade 3) in
the infarct vessel at 90 min after initiation of thrombolysis is
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associated with a lower mortality than an occluded infarct
vessel or TIMI grade 2 flow (3–5). However, current
thrombolytic regimens are limited by the fact that only 35%
to 60% of patients experience optimal early reperfusion, and
about 10% of reperfused vessels reocclude during hospital
stay, which is associated with increased morbitidy and
mortality (6,7).
Streptokinase is still the most often used thrombolytic
agent worldwide. With streptokinase early reperfusion will
occur in less than 40% of cases, leaving more room for
improvement by better adjunctive therapy than with recom-
binant tissue-type plasminogen activator. Improvements in
adjunctive therapy have been attempted by better platelet
inhibition and more specific thrombin inhibitors. More
specific thrombin inhibition may be most relevant because
of ongoing thrombin formation and activation during
thrombolysis, which is not completely suppressed by IV
heparin (8). Unlike heparin, the specific thrombin inhibitor
hirudin acts independently of antithrombin III, is not
inactivated by platelet factor IV and, most importantly,
inhibits both free and clot-bound thrombin (9).
In the present study a recombinant hirudin (HBW 023,
lepirudin) has been tested as an adjunct to streptokinase
thrombolysis for AMI. Previous trials (10–12) had shown a
narrow therapeutic range for hirudin, resulting in an unac-
ceptably high rate of bleedings with higher doses. The
combined analysis of TIMI-9B and GUSTO-IIB (Global
Use of Strategies to Open Occluded coronary arteries in
acute coronary syndromes) in patients receiving thrombo-
lytic therapy and reduced hirudin doses showed a significant
(14%) reduction in the incidence of reinfarctions within 30
days compared with heparin, but no significant differences
in mortality (13,14).
A major problem of most phase II trials is their limited
information on safety of a new thrombolytic regimen. Given
that the size of invasive studies is limited by the availability
of resources, novel approaches are needed to resolve this
dilemma. In this trial, coronary patency was determined in
one-third of the patients, whereas indirect evidence of
successful reperfusion by ST-segment analysis and close
monitoring for adverse events was performed in all patients.
PATIENTS AND METHODS
Study population. The study was a prospective, random-
ized, double-blind, international multicenter trial in male
and female patients with AMI aged 18 to 75 years. The
study protocol was approved by the Ethics Committee of
the University of Go¨ttingen and by the relevant institutional
review boards of the participating centers. It was conducted
according to good clinical practice guidelines, including
source data audit. All patients gave witnessed or written
consent.
The time interval between symptom onset and start of
therapy was to be less than 6 h. A ST-segment elevation
$0.2 mV in at least two precordial leads or ST-segment
elevation $0.1 mV in at least two limb leads had to be
present, and the patient had to give informed consent before
inclusion into the study. Exclusion criteria were in addition
to the usual contraindications to thrombolysis: streptokinase
therapy during the last year, heparin therapy within 2 h
before study medications and known renal insufficiency
(serum creatinine .2.0 mg/dl or 1.77 mmol/liter). Hyper-
lipidemia was reported as stated by the investigators in the
case record form; no further definition was made.
Treatment protocol. Patients were randomized by tele-
phone in Germany or according to the medication number
outside Germany. All patients were to receive a loading dose
of 300 mg of aspirin followed by 100 to 200 mg daily. The
IV bolus dose of lepirudin (0.2 mg/kg body weight) or
matching placebo was given before streptokinase (1.5 mil-
lion units in 60 min intravenously). Subcutaneous lepirudin
0.5 mg/kg or unfractionated heparin 12,500 IE were given
twice daily over five to seven days starting within 30 min
after the start of streptokinase. Subcutaneous (SC) injec-
tions were given at 12-h intervals according to the activated
partial thromboplastin time (aPTT) target value of two
times normal. A SC injection had to be left out if the aPTT
ratio was greater than 2.5 before the third or greater than 2
before the fourth or the following SC injections. After the
SC injection had been left out, the aPTT ratio had to be
remeasured 12 h later. If the aPTT ratio was still above 1.5,
the study medication had to be terminated. The lepirudin
dose of 0.5 mg/kg given subcutaneously twice daily has been
shown to produce mean plasma concentrations of 300 to
400 ng/ml and mean aPTT values of 50 to 75 s in healthy
volunteers (unpublished data).
Study end points. The primary end point was early and
complete patency defined as the proportion of patients with
TIMI-3 flow in the infarct-related artery 90 min after start
of study medication (15). The angiograms were assessed
centrally in a core lab by at least two blinded experienced
investigators.
Secondary end points were the combined and individual
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
aPTT 5 activated partial thromboplastin time
CI 5 confidence interval
ECG 5 electrocardiogram
GUSTO 5 Global Use of Strategies to Open Occluded
coronary arteries in acute coronary
syndromes
HERO 5 Hirulog Early Reperfusion/Occlusion Study
HIT 5 Hirudin for the Improvement of
Thrombolysis
PTCA 5 percutaneous transluminal coronary
angioplasty
SC 5 subcutaneous
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967JACC Vol. 34, No. 4, 1999 Neuhaus et al.
October 1999:966–73 Lepirudin vs. Heparin After Streptokinase
incidences of death, nonfatal stroke, nonfatal reinfarction,
rescue percutaneous transluminal coronary angioplasty
(PTCA) or refractory angina pectoris within 30 days after
randomization; the individual incidences of hemorrhagic
and nonhemorrhagic strokes; the proportion of patients
with complete resolution of ST-segment elevation at 90 (70
to 110) and 180 (120 to 240) min and one-year mortality.
Refractory angina was defined as recurrent chest pain of
more than 5 min duration with electrocardiogram (ECG)
changes occurring in the presence of “optimum” medical
treatment and requiring an additional intervention in the
view of the responsible physician.
The ST-segment resolution was assessed blindly and
centrally (by author R.S.) as previously described (16).
Complete ST-segment resolution was defined as $70%
resolution of ST elevation compared with the sum of ST
elevation in the baseline ECG, partial ST resolution as 30%
to 70% resolution of ST elevation and no ST resolution as
,30% of ST elevation.
Major bleeding was defined as any bleeding that was fatal
or life-threatening; intracranial, permanently or significantly
disabling; or bleeding necessitating surgical intervention or
requiring transfusion of two or more units of packed red
cells. All other bleedings were classified as minor.
Statistical analysis. If not specifically mentioned, results
are based on an intention-to-treat analysis. The per protocol
analysis included only patients who had the required
amount of ST elevations in the baseline ECG, who received
at least 750,000 units of streptokinase and who were given
at least the IV bolus and the first SC injection of the
double-blind study medication.
The primary angiographic end point was to be obtained
in a subset of 400 patients, based on the assumption of a
TIMI-3 rate of 35% in the placebo-heparin group versus
50% in the lepirudin group (two-sided Fisher exact test,
significance level 5%, power 84%).
For the combined clinical end point the sample size of
1,200 patients is sufficient to detect an event reduction from
20% in the placebo-heparin group to 15% in the lepirudin
group (significance level 5%, power 79%).
For comparison of two dependent/independent samples,
either the Wilcoxon signed rank-sum test/Mann-Whitney
U test or the Fisher exact test was applied. For comparisons
of three or more independent samples, we used the Kruskal-
Wallis test.
RESULTS
Patients. A total of 1,208 patients were randomized from
April 17, 1995 to December 7, 1996, in 64 centers in seven
European countries; 447 of these patients were entered into
the angiographic part of the trial.
The age at inclusion date ranged from 30 to 92 years,
with a mean age of 61 years; 76% of the patients were men.
The treatment groups in the angiographic substudy were
well matched with regard to their baseline characteristics
and did not differ from the total study population (Table 1).
Study treatment. Ninety-eight percent of all patients re-
ceived 1.5 million units of streptokinase; only 0.9% did not
receive any streptokinase at all. Aspirin was given to 99.5%
of the patients. Eight patients in the lepirudin and four in
the heparin group did not receive the IV bolus of study
treatment. The IV bolus of study medication was given
before the streptokinase infusion in 98% of patients. The
time between the IV bolus of study medication and start of
streptokinase was 2.64 6 4.47 min in the lepirudin and
2.83 6 4.00 min in the heparin group. There were no
significant differences in the duration of SC injections
Table 1. Clinical Characteristics of the Entire Study Population and Patients Enrolled in the Angiographic Part
Total Study (n 5 1208) Angio Substudy (n 5 447)
Lepirudin (n 5 603) Heparin (n 5 605) Lepirudin (n 5 227) Heparin (n 5 220)
Age (yr) 61.1 6 11.6 61.3 6 11.9 60.2 6 11.6 61.6 6 10.7
Men (%) 76.0 75.9 79.7 73.6
Medical history
Hypertension 39.6%* 34.2%* 42.3%** 28.6%**
Diabetes 12.9% 13.4% 11.5% 15.0%
Hyperlipidemia 25.0% 24.5% 22.9% 28.2%
Current smoker 43.3% 45.0% 41.4% 42.7%
Previous MI 12.1% 14.5% 12.8% 11.8%
Previous PTCA or CABG 4.3% 5.6% 5.3% 5.9%
Conditions at randomization
Heart rate (beats/min) 77.1 6 17.5 76.8 6 18.4 76.8 6 17.6 76.4 6 18.5
Systolic blood pressure (mm Hg) 138 6 26 137 6 24 139 6 28 138 6 24
Killip class .1 (%) 12.4 11.4 10.6 15.0
Anterior MI (%) 38.9 41.6 44.1 41.8
Time to treatment (min) 172 6 77 168 6 80 178 6 82 174 6 79
*p 5 0.003; **p 5 0.048; all other differences p . 0.1 5 NS.
CABG 5 coronary artery bypass graft; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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between the two groups. The SC therapy with lepirudin was
interrupted or terminated in 237 patients and that with
heparin in 201 patients. The most frequent reason given by
the investigators was a high aPTT (42.6% in the lepirudin
vs. 33.7% in the heparin group). Termination of study
treatment due to prolongation of aPTT beyond the pre-
defined value was observed more often in the lepirudin
group (4.4% vs. 0.8%).
Angiographic findings. A total of 447 patients in 25
centers were enrolled in the angiographic substudy. For
various reasons 19 (4.2%) patients had no 90-min angio-
gram. The infarct-related artery could not be identified in
10 patients, leaving 418 (93.5%) patients, 209 in each group,
with TIMI flow grading of the infarct-related artery. The
mean time between start of streptokinase infusion and
angiogram was 90 min (median 90 min, 95% reference
interval 70 to 125 min), without any differences between the
treatment groups.
The proportions of the infarct-related arteries were evenly
distributed between the lepirudin- and heparin-treated pa-
tients (left anterior descending coronary artery 38.8% vs.
36%; right coronary artery 39.7% vs. 43%; left circumflex
coronary artery 14% vs. 14%; others 7.5% vs. 7%).
Complete patency (TIMI grade 3 flow) of the infarct-
related artery was observed in 40.7% (85/209, 95% CI
[confidence interval] 33.9% to 47.7%) of the lepirudin-
treated patients and 33.5% (70/209, 95% CI 27.1% to
40.3%) of the heparin-treated patients (p 5 0.16) (Fig. 1).
In patients treated within 180 min after symptom onset
both with lepirudin (51/118 5 43.2%) and heparin (49/
133 5 36.8%) higher TIMI 3 patency rates were observed
than in patients treated after more than 180 min with
lepirudin (34/91 5 37.4%) or heparin (21/76 5 27.6%), but
these differences were not statistically significant.
Analysis of patients treated per protocol (n 5 342)
revealed a significant difference in favor of lepirudin versus
heparin for TIMI 3 flow at 90 min (76/175 5 43.4%, 95%
CI 36 to 51.1%, vs. 54/167 5 32.3%, 95% CI 25.3% to
40.0%, p 5 0.045).
ST-segment resolution analysis. All 1,208 patients were
considered for this analysis. In 140 patients, the prerandom-
ization ECG was not evaluable for ST-resolution analyses,
mainly because the ECGs did not show the required
amount of ST-segment elevation. For various reasons, 164
patients had to be excluded from evaluation of the 90-min
ECG and 70 patients from evaluation of the 180-min
ECG, mostly because of ECGs recorded outside the re-
spective time windows. Thus, 904 and 998 patients form the
basis for evaluation at 90 and 180 min, respectively. The ST
resolutions at both time points were significantly different in
favor of lepirudin (Table 2). More patients had complete
and fewer patients had no ST resolution, and the average
ST elevation recovery from baseline to 90 as well as to
180 min was significantly greater in the lepirudin group.
The differences between lepirudin- and heparin-treated
patients for complete ST resolution after 90 min (28% vs.
22%, p 5 0.05) and no ST resolution after 180 min (13% vs.
18%, p 5 0.035) were statistically significant.
Clinical events. Table 3 shows the incidence of major
clinical events during the 30-day study period and the
mortality rate at one year. No significant differences existed
for the prespecified cardiac end points and all-cause mor-
Figure 1. Comparison of the 90-min patency rates of the infarct-
related artery in patients treated with streptokinase and lepirudin
or heparin. Solid box, heparin (n 5 209); striped box, lepirudin
(n 5 209).
Table 2. Results of the ECG Substudy: Incidence of Complete, Partial and No ST Resolution
at 90 min and 180 min in Patients Allocated to Lepirudin or Heparin Treatment
ST Resolution
At 90 min At 180 min
Lepirudin
(n 5 445)
Heparin
(n 5 459)
Lepirudin
(n 5 500)
Heparin
(n 5 498)
Complete 123 (28%) 101 (22%) 259 (52%) 237 (48%)
Partial 140 (32%) 143 (31%) 176 (35%) 172 (35%)
Number 182 (41%) 215 (47%) 65 (13%) 89 (18%)
p Value 0.03 0.07
S ST resolution* 41% (9–73) 33% (1–65) 71% (51–92) 69% (41–88)
p Value 0.008 0.03
*Median values (25th and 75th percentiles).
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tality at 30 days and at one year. The risk reduction of the
combined end point was 6.6% with lepirudin (22.7% vs.
24.3%).
The reinfarction rate during the five days of study
treatment was lower in the lepirudin group (1% vs. 2.5%,
p 5 0.048) but similar at 30 days (Fig. 2). The combined
incidences of death or nonfatal reinfarction at 30 days were
10.4% and 11% in lepirudin- and heparin-treated patients,
respectively.
Safety. Seven strokes occurred in the lepirudin group and
nine occurred in the heparin group. Only one patient in the
lepirudin group and two patients in the heparin group
suffered a hemorrhagic stroke; all three patients died. The
incidences of major and minor bleedings were similar in
both treatment groups (Table 4). Most of the major
bleedings were puncture-site related (55% in the lepirudin
group and 66% in the heparin group, respectively).
DISCUSSION
The purpose of this study was twofold: to compare lepirudin
and heparin as adjuncts to streptokinase thrombolysis, and
to evaluate a modified approach for phase II studies for
thrombolytic regimens in patients with AMI.
Hirudin has been shown to improve coronary patency
with streptokinase in animal models (17). In the TIMI 6
trial, hirudin was as safe as heparin as adjunct to streptoki-
nase, and a trend toward an improved clinical outcome with
hirudin was observed (18). Our study was based on the
results of the Hirudin for the Improvement of Thrombolysis
(HIT-SK [streptokinase]) trial, in which lepirudin com-
pared with heparin improved 90-min patency after strep-
tokinase therapy, but no clear dose relationship was ob-
served (19). Because a hirudin bolus of $0.4 mg/kg as
adjunct to thrombolysis had been shown to increase the
bleeding risk, especially the rate of intracranial bleedings
(10–12), and because a reduced bolus dose of 0.1 mg/kg was
safe but did not improve clinical outcome in the TIMI 9B
study (13), the therapeutic window for hirudin seems rather
narrow. Therefore, we chose the bolus dose of 0.2 mg/kg to
improve early reperfusion.
In addition, based on pharmacologic studies, SC injec-
tions aimed at a prolongation of the aPTT to 1.5 to 2.5
times control were given to diminish the rate of reocclusions
and reinfarctions. The TIMI 3 patency at 90 min in the
patients treated with heparin was 33%, which is similar to
that observed in the GUSTO-I angiographic study after
streptokinase and SC heparin (4). With lepirudin there was
an improvement of TIMI 3 flow to 41%, which was
statistically not significant. However, if only patients treated
per protocol (in this analysis patients without the required
amount of ST elevations were excluded) were included in
the analysis, the advantage of lepirudin (43.4%) versus
heparin (32.3%) was statistically significant. This patency
rate with lepirudin is somewhat lower than the 47% TIMI
3 patency with streptokinase and another direct thrombin
inhibitor, hirulog, in the Hirulog Early Reperfusion/
Occlusion (HERO) study (20). However, the angiograms in
the HERO trial were obtained somewhat later at 108 6
24 min compared with 90 6 18 min in our study, so that
ongoing thrombolysis is a likely explanation for the higher
patency rate with hirulog.
In addition to the improved TIMI 3 patency with
lepirudin, a significantly greater resolution of ST elevation,
Table 3. Clinical Events During the 30-Day Study Period and
One-Year Mortality
Lepirudin
(n 5 603)
Heparin
(n 5 605)
p
Value
Death 41 (6.8%) 39 (6.4%) NS
Cardiac death 36 (6.0%) 33 (5.5%) NS
Reinfarction 28 (4.6%) 31 (5.1%) NS
Cardiogenic shock 17 (2.9%) 18 (3.0%) NS
Refractory angina 22 (3.6%) 18 (3.0%) NS
Recurrent angina 63 (10.6%) 54 (9.0%) NS
Rescue-PTCA 45 (7.5%) 49 (8.1%) NS
Combined end point* 137 (22.7%) 147 (24.3%) NS
Death 1 year 59 (9.8%) 54 (8.9%) NS
*Combined end point: death, nonfatal stroke, nonfatal reinfarction, rescue-PTCA or
refractory angina.
Abbreviations as in Table 1.
Figure 2. Cumulative rate of reinfarctions during the five days of
study treatment and until day 30. After five days the difference
between the lepirudin group and heparin group was statistically
significant (p 5 0.048).
Table 4. Safety Variables Within 30 Days After Treatment
Lepirudin
(n 5 603)
Heparin
(n 5 605) p Value
Total stroke 7 (1.2%) 9 (1.5%) NS
Hemorrhagic stroke 1 (0.2%) 2 (0.3%) NS
Ischemic stroke 6 (1.0%) 7 (1.1%) NS
Major bleeding 20 (3.3%) 21 (3.5%) NS
Minor bleeding 89 (14.8%) 70 (11.6%) NS
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an independent marker for myocardial perfusion, was ob-
served both at 90 min and 180 min after start of thrombol-
ysis. Thus, both markers of early reperfusion, patency and
ST resolution showed a strong trend toward superiority of
lepirudin over heparin for the early restoration of blood flow
in the infarct vessel after streptokinase therapy. These
results were achieved without any increase in bleeding
complications, which had been a major concern after the
experience of an increased rate of cerebral hemorrhages with
the combination of lepirudin and recombinant tissue-type
plasminogen activator in the HIT-3 trial (10).
It also has to be noted that the rate of hemorrhagic
strokes was very low, both in the lepirudin (0.2%) group and
heparin (0.3%) group, compared with the 0.6% intracranial
bleeding rate observed with streptokinase and hirudin in the
GUSTO-IIb trial. This might, at least in part, be due to the
fact that the patients in our trial were somewhat younger
compared with patients who received streptokinase in the
GUSTO-IIb trial (mean age 61 years vs. 64 years). Al-
though the sample size of 600 patients does not allow
assessment of the true incidence of these rare events, the
observed intracranial hemorrhage rate of 0.17% in the
lepirudin group excludes a rate of more than 0.93% at the
5% level of significance.
In summary, the reduced lepirudin-bolus dose of
0.2 mg/kg, followed by SC injections with close aPTT
monitoring, seems to be as safe as SC heparin, which is
current clinical practice in most hospitals after streptokinase
thrombolysis.
The rate of reinfarctions during the five days of study
treatment was significantly diminished with lepirudin, but
was similar at the end of the study period at day 30. The
reason might be a more potent thrombin inhibition with
lepirudin during the treatment phase, and a catch-up effect
after cessation of therapy, as has been observed in previous
trials with direct thrombin inhibitors (21). In contrast, in a
combined analysis of the GUSTO-IIb and the TIMI 9B
studies, a moderate but significant 14% reduction of rein-
farctions with hirudin was still present at 30 days.
However, the early advantage of lepirudin did not trans-
late into an improvement in clinical outcome at 30 days or
at one year. These findings are different from the results of
a subgroup analysis of the GUSTO-IIb study, which
showed a 28% reduction in death and a 46% reduction in
reinfarction in 530 patients treated with streptokinase and
hirudin in comparison with 552 patients treated with
streptokinase and heparin (22). This strikingly large differ-
ence in a post hoc analysis in favor of hirudin may be due to
a particularly high event rate of 14.4% (30-day mortality or
reinfarction), especially an uncommonly high rate of rein-
farctions (8.4%), in the streptokinase/heparin group in
GUSTO-IIb.
In our prospective study this combined 30-day mortality
and reinfarction rate was 10.4% and 11% in the hirudin and
heparin groups, respectively. Because lepirudin was given
before thrombolysis in almost all our patients, the timing of
administration of hirudin does not explain the difference to
the GUSTO-IIb trial, where the study drug was given a
mean of 35 min after thrombolysis. Pharmacologic studies
with lepirudin did not show any significant differences for
mean plasma levels (410 ng/ml vs. 400 ng/ml) and mean
aPTT prolongations (aPTT ratio 2 vs. 2.1) between a
continuous IV infusion of 0.1 mg/kg/h and SC administra-
tion of 0.5 mg/kg twice daily (unpublished data). In our
study, higher aPTTs were seen under lepirudin treatment
compared to heparin treatment; therefore, inadequate dos-
ing or ineffective anticoagulation by SC administration
lepirudin does not seem to be an issue. Hence, the apparent
difference between our study and GUSTO-IIb may be due
to a chance finding of the retrospective analysis in GUSTO-
IIb.
In summary, specific thrombin inhibition with lepirudin
tends to accelerate infarct vessel patency induced by strep-
tokinase, without an increase in major bleeding complica-
tions. This early benefit was not associated with a significant
improvement in clinical outcome at 30 days.
Size and design of phase II trials. The second problem
addressed in the HIT-4 trial was the adequate design and
sample size of phase II trials. Dose-finding studies for
thrombolytic regimens in patients with AMI are primarily
designed to identify the most effective dose of a new
thrombolytic or adjunctive agent (23). The current gold
standard for efficacy is early (60 to 90 min) angiographic
infarct vessel patency (24). The size of invasive studies is
limited by the availability of resources; thus, novel ap-
proaches are needed to resolve this problem (25). In
addition to coronary patency, further noninvasive surrogate
end points for efficacy are required. Early ST-segment
resolution is a highly significant predictor of survival after
acute myocardial infarction and can be used to compare
thrombolytic regimens (26).
In our study, results of both efficacy parameters were
consistent, underscoring the value of ST resolution as a
surrogate end point. The safety profile of a new reperfusion
regimen can only be assessed by a substantial increase in
sample size of phase II trials. In settings where invasive
markers of efficacy are used, only limited numbers of
patients can be investigated owing to the availability of
resources. The inclusion of a larger number of patients not
studied invasively (a so-called safety cohort) is an alternative
that we used in our study. The sample size of over 600
patients in both treatment groups seems sufficient to get a
realistic estimate of the safety of a new regimen compared
with a standard therapy, in our case streptokinase with SC
heparin. To detect a 20% increase in the rate of intracranial
hemorrhages, which was 0.33% in the heparin group, we
would need 95,000 patients to achieve a power of 80% with
a p level of 0.05. Obviously, this number of patients is
unrealistic for clinical trials. Our modified approach, com-
bining invasive and noninvasive efficacy parameters and
including a safety cohort, may facilitate the search for
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improved reperfusion treatment strategies in patients with
AMI.
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